A Phase 2 interventional study of diacerein 1% ointment and A placebo ointment in Epidermolysis Bullosa Simplex, sponsored by Castle Creek Pharmaceuticals, LLC. Terminated at 22 sites in 8 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2019-11-05.
Sponsored by Castle Creek Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Epidermolysis Bullosa Simplex with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Epidermolysis Bullosa Simplex · United States.
Among the 11 studies in Epidermolysis Bullosa Simplex with a site in United States, this one is one of 3 that started in 2017, is one of 5 in phase 2, and was the 3rd registered.
20 studies on the registry are indexed under Epidermolysis Bullosa Simplex; 5 are open to participants now.
Browse Epidermolysis Bullosa Simplex studies →3 of the 11 studies in Epidermolysis Bullosa Simplex with a site in United States are open now. Recruiting first, the newest first:
BioMendics, LLC · Sites in United States
Ages 2+
Joyce Teng · Sites in United States
Ages 0+ · Healthy volunteers
Stanford University · Sites in United States
Ages 6 mo+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Epidermolysis Bullosa Simplex studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1
First in 2015; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 19 across 17 interventional studies indexed under Epidermolysis Bullosa Simplex.
Median enrollment 11 across the 9 interventional studies, 30 across the 2 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 7 most frequent:
Castle Creek Pharmaceuticals, LLC is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Castle Creek Pharmaceuticals, LLC has 3 studies filed under Epidermolysis Bullosa Simplex — fewer than ten, so there is no comparison to draw.
2 of the studies in Epidermolysis Bullosa Simplex with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT07756138Stanford UniversityFilsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex | 2027-01-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Epidermolysis Bullosa Simplex with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.
The study is an international, multicenter, randomized, double-blind, vehicle-controlled, parallel group study to evaluate the safety and efficacy of diacerein 1% ointment for the treatment of subjects with EBS. Participants were assigned to study groups receiving either diacerein 1% ointment or vehicle ointment for 8 weeks, followed by an 8 week follow-up period. Approximately 80 subjects were to be randomized to one of the 2 treatment groups.
The primary objective of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment based on reduction in body surface area (BSA) of EBS lesions being treated when applied once-daily for 8 weeks in subjects with EBS. The secondary objectives are to compare the effects of diacerein 1% ointment to vehicle ointment in subjects with EBS in changes in Investigator Global Assessment (IGA) scores, pain, pruritus, mobility, and safety and tolerability.
Key Inclusion Criteria:
Subject has an Assessment Area of EBS lesions to be treated, that is ≥2% body surface area (BSA) and the EBS lesions are in one or both of the following body areas:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
diacerein 1% ointment will be used for 8 weeks
Drug: diacerein 1% ointment
vehicle ointment will be used for 8 weeks
Drug: A placebo ointment
diacerein 1% ointment administered topically
Also known as: CCP-020
vehicle ointment administered topically
Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area
Analysis of the proportion of subjects who achieved a ≥60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8
Time frame: Baseline to Week 8
The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA)
The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as ≥2-point reduction from Baseline to Visit 6 (Week 8). IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe Minimum score = 0 Maximum score = 4; higher score = worse outcome
Time frame: Baseline to Week 8
| Milestone | Diacerein 1% Ointment | Vehicle Ointment |
|---|---|---|
| Started | 28 | 26 |
| Completed | 21 | 21 |
| Not completed | 7 | 5 |
Analysis of the proportion of subjects who achieved a ≥60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8
| Participants | Diacerein 1% Ointment | Vehicle Ointment |
|---|---|---|
| Proportion of Subjects Who Achieved ≥ 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area | 16 | 14 |
The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as ≥2-point reduction from Baseline to Visit 6 (Week 8). IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe Minimum score = 0 Maximum score = 4; higher score = worse outcome
| Participants | Diacerein 1% Ointment | Vehicle Ointment |
|---|---|---|
| The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA) | 12 | 7 |
Collected over Baseline to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diacerein 1% Ointment | 0/28 (0%) | 0/28 (0%) | 16/28 (57.1%) |
| Vehicle Ointment | 0/26 (0%) | 2/26 (7.7%) | 15/26 (57.7%) |
| Event | Diacerein 1% Ointment | Vehicle Ointment |
|---|---|---|
| Humerus fractureInjury, poisoning and procedural complications | 0/28 | 1/26 |
| Meniere's DiseaseEar and labyrinth disorders | 0/28 | 1/26 |
| Event | Diacerein 1% Ointment | Vehicle Ointment |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/28 | 2/26 |
| VomitingGastrointestinal disorders | 4/28 | 1/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/28 | 1/26 |
| Skin InfectionInfections and infestations | 3/28 | 3/26 |
| HeadacheNervous system disorders | 1/28 | 3/26 |
| FallInjury, poisoning and procedural complications | 0/28 | 3/26 |
| DiarrhoeaGastrointestinal disorders | 3/28 | 0/26 |
| PruritusSkin and subcutaneous tissue disorders | 3/28 | 1/26 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 2/28 | 2/26 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/28 | 2/26 |
All efficacy endpoints were based on the Assessment Area, defined in the protocol, unless otherwise stated. The Intent to Treat (ITT) Population was used for these analyses.
| Age, Customized(Participants) | Diacerein 1% Ointment | Vehicle Ointment | Total |
|---|---|---|---|
| Age <8 years old | 13 | 12 | 25 |
| Age greater than or equal to 8 years old | 15 | 14 | 29 |
| Sex: Female, Male(Participants) | Diacerein 1% Ointment | Vehicle Ointment | Total |
|---|---|---|---|
| Female | 14 | 16 | 30 |
| Male | 14 | 10 | 24 |
| Race (NIH/OMB)(Participants) | Diacerein 1% Ointment | Vehicle Ointment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 24 | 23 | 47 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Baseline BSA(Body Surface Area) of EBS(Epidermolysis Bullosa Simplex) Lesions within Assessment Area(Percent of BSA) | Diacerein 1% Ointment | Vehicle Ointment | Total |
|---|---|---|---|
| Mean | 5.76 ± 4.674 | 7.13 ± 7.606 | 6.42 ± 6.237 |
| Baseline IGA Score of 3 or 4(Participants) | Diacerein 1% Ointment | Vehicle Ointment | Total |
|---|---|---|---|
| IGA Score: 3 | 26 | 24 | 50 |
| IGA Score: 4 | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Oct 2018, 16 months.
Results were first posted in Nov 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diacerein
Epidermolysis Bullosa Simplex →
Castle Creek Pharmaceuticals, LLC